Studied in registered human trials with published pharmacokinetic data, but not approved. Dosing outside a trial protocol has no established safety margin.
FLAG: A half-life of ~6-7 days is widely cited but I could NOT trace it to an allowed primary source (it appears in the Journal of Hepatology cirrhosis PK paper, a non-permitted host). Reported null. C18 fatty-acid acylation and >99% albumin binding support once-weekly dosing. MW 4232 from PubChem name lookup.
Phase 2 programs (obesity, MASH) titrate once-weekly SC toward maintenance doses up to ~4.8 mg. Investigational; exact per-administration range depends on trial arm.
Preclinical pharmacology (PMC9679702) plus phase 2 clinical trials; no regulatory label. Half-life not traceable to an allowed primary source.
Investigational; no boxed warning. Trial adverse events predominantly gastrointestinal; glucagon-agonist activity may increase heart rate. Not for clinical dosing decisions.